Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback